JEMPERLI was studied in the largest monotherapy trial of a PD-1 inhibitor in endometrial cancer to date, GARNET1-3

A global, multicenter, multiple cohort, open-label study1,3

Patient Population (n=71)

  • Female patients age ≥18 years
  • Recurrent or advanced endometrial cancer that had progressed on or following treatment with a platinum-containing regimen
  • Tumors that were mismatch repair deficient as determined by IHC testing. The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay


500 mg every 3 weeks
for 4 doses, followed by
1000 mg every 6 weeks*

Key Efficacy Endpoints


  • Overall response rate (ORR)
  • Duration of response (DOR)


*Treatment continued until disease progression or unacceptable toxicity.1

As assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.1

Key Inclusion and Exclusion Criteria1,3

GARNET Cohort 1: dMMR endometrial cancer

Inclusion criteria

  • Patients must have had:
    • Recurrent or advanced endometrial cancer
    • dMMR endometrial cancer as determined by IHC testing
    • Progression on or after platinum-containing regimen
    • ≤2 lines of prior anticancer treatment for recurrent or advanced disease

Exclusion criteria

  • Patients could not have had:
    • Prior treatment with PD-1/PD-L1blocking antibodies or other immune checkpoint inhibitor therapy
    • Autoimmune disease that required systemic treatment within 2 years

PD-L1=programmed death ligand 1; PD-1=programmed death receptor 1.

90% of patients had received prior anticancer surgery and 79% had received prior anticancer radiotherapy. Approximately 40% of patients had 2 lines or more of prior anticancer treatment in total. Approximately 11% of patients had received 3 total prior regimens and 4% had received 4 or more total prior regimens.1

GARNET Cohort 1: Patient baseline characteristics1,3

Efficacy population baseline characteristics (n=71)1,3

Of the 104 patients in the study with dMMR endometrial cancer who received JEMPERLI, 71 were included in the efficacy analysis.1,3,4

JEMPERLI (dostarlimab-gxly) Common Histology Chart

ECOG=Eastern Cooperative Oncology Group; FIGO=International Federation of Gynecology and Obstetrics.

Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Learn about response with

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety and
tolerability profile of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.